Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

2.440 -0.230 (-8.61%)
Streaming Delayed Price Updated: 11:21 AM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
"Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy” Featuring GeoVax CEO David Dodd on May 28, 2026 
Via TheNewswire.com
News headline image
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!
Via AB Newswire
Topics Artificial Intelligence
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness
Via AB Newswire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen 
Via NewMediaWire
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen 
Via TheNewswire.com
News headline image
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Company Aligns Resources With Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum 
Via TheNewswire.com
News headline image
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses 
Via TheNewswire.com
News headline image
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
WHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities 
Via TheNewswire.com
News headline image
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA - May 18, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered into a... 
Via TheNewswire.com
News headline image
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
ATLANTA, GA - May 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,... 
Via TheNewswire.com
Topics Supply Chain
News headline image
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors
Company Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential 
Via TheNewswire.com
News headline image
GeoVax Announces a Warrant Inducement Transaction
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA - May 7, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant... 
Via TheNewswire.com
News headline image
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization 
Via TheNewswire.com
News headline image
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
Near-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation 
Via TheNewswire.com
News headline image
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
Positioned to Enhance Efficacy of Checkpoint Inhibitors and Next-Generation Oncology Modalities Across Solid Tumors 
Via TheNewswire.com
News headline image
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine) 
Via TheNewswire.com
News headline image
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy Supply Chain
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide 
Via TheNewswire.com
Topics Economy Supply Chain
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.